190 related articles for article (PubMed ID: 38467982)
1. Development of Immune Cell Therapy Using T Cells Generated from Pluripotent Stem Cells.
Kawamoto H; Masuda K; Nagano S
Adv Exp Med Biol; 2024; 1444():207-217. PubMed ID: 38467982
[TBL] [Abstract][Full Text] [Related]
2. Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology.
Kawamoto H; Masuda K; Nagano S
Int Immunol; 2021 Nov; 33(12):827-833. PubMed ID: 34661676
[TBL] [Abstract][Full Text] [Related]
3. Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.
Itoh M; Kawagoe S; Nakagawa H; Asahina A; Okano HJ
Exp Dermatol; 2023 Feb; 32(2):126-134. PubMed ID: 36222007
[TBL] [Abstract][Full Text] [Related]
4. Cloning and expansion of antigen-specific T cells using iPS cell technology: development of "off-the-shelf" T cells for the use in allogeneic transfusion settings.
Kawamoto H; Masuda K; Nagano S; Maeda T
Int J Hematol; 2018 Mar; 107(3):271-277. PubMed ID: 29388165
[TBL] [Abstract][Full Text] [Related]
5. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes.
Maeda T; Nagano S; Kashima S; Terada K; Agata Y; Ichise H; Ohtaka M; Nakanishi M; Fujiki F; Sugiyama H; Kitawaki T; Kadowaki N; Takaori-Kondo A; Masuda K; Kawamoto H
Mol Ther Methods Clin Dev; 2020 Dec; 19():250-260. PubMed ID: 33102617
[TBL] [Abstract][Full Text] [Related]
6. [Mass-Production of Tumor Antigen-Specific Cytotoxic T Lymphocytes Using the iPS Cell Technology-Development of "Off-the-Shelf T Cells"for the Use in Allogeneic Transfusion Settings].
Kawamoto H; Nagano S
Gan To Kagaku Ryoho; 2019 Nov; 46(11):1677-1682. PubMed ID: 31748471
[TBL] [Abstract][Full Text] [Related]
7. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
[TBL] [Abstract][Full Text] [Related]
8. Differentiating CD8αβ T Cells from TCR-Transduced iPSCs for Cancer Immunotherapy.
Minagawa A; Kaneko S
Methods Mol Biol; 2019; 2048():81-84. PubMed ID: 31396932
[TBL] [Abstract][Full Text] [Related]
9. The Generation of Human γδT Cell-Derived Induced Pluripotent Stem Cells from Whole Peripheral Blood Mononuclear Cell Culture.
Watanabe D; Koyanagi-Aoi M; Taniguchi-Ikeda M; Yoshida Y; Azuma T; Aoi T
Stem Cells Transl Med; 2018 Jan; 7(1):34-44. PubMed ID: 29164800
[TBL] [Abstract][Full Text] [Related]
10. [Mass-Production of Cytotoxic T Lymphocytes Regenerated from Pluripotent Stem Cells-To Target Solid Tumors].
Kashima S; Masuda K; Kawamoto H
Gan To Kagaku Ryoho; 2020 Oct; 47(10):1415-1420. PubMed ID: 33130732
[TBL] [Abstract][Full Text] [Related]
11. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy.
Minagawa A; Yoshikawa T; Yasukawa M; Hotta A; Kunitomo M; Iriguchi S; Takiguchi M; Kassai Y; Imai E; Yasui Y; Kawai Y; Zhang R; Uemura Y; Miyoshi H; Nakanishi M; Watanabe A; Hayashi A; Kawana K; Fujii T; Nakatsura T; Kaneko S
Cell Stem Cell; 2018 Dec; 23(6):850-858.e4. PubMed ID: 30449714
[TBL] [Abstract][Full Text] [Related]
12. A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy.
Iriguchi S; Yasui Y; Kawai Y; Arima S; Kunitomo M; Sato T; Ueda T; Minagawa A; Mishima Y; Yanagawa N; Baba Y; Miyake Y; Nakayama K; Takiguchi M; Shinohara T; Nakatsura T; Yasukawa M; Kassai Y; Hayashi A; Kaneko S
Nat Commun; 2021 Jan; 12(1):430. PubMed ID: 33462228
[TBL] [Abstract][Full Text] [Related]
13. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
[TBL] [Abstract][Full Text] [Related]
14. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
Lahimchi MR; Maroufi F; Maali A
Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
[TBL] [Abstract][Full Text] [Related]
15. In vivo programming of tumor antigen-specific T lymphocytes from pluripotent stem cells to promote cancer immunosurveillance.
Lei F; Zhao B; Haque R; Xiong X; Budgeon L; Christensen ND; Wu Y; Song J
Cancer Res; 2011 Jul; 71(14):4742-7. PubMed ID: 21628492
[TBL] [Abstract][Full Text] [Related]
16. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
Nianias A; Themeli M
Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
[TBL] [Abstract][Full Text] [Related]
17. Efficient Generation of iPSC-Derived Hematoendothelial Progenitors and Specification Toward T cell Lineage.
Suwanpitak S; Promnakhon N; Netsrithong R; Wattanapanitch M
Methods Mol Biol; 2022; 2454():423-442. PubMed ID: 33755900
[TBL] [Abstract][Full Text] [Related]
18. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
Ando M; Nakauchi H
Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
[TBL] [Abstract][Full Text] [Related]
19. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
[TBL] [Abstract][Full Text] [Related]
20. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
